Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Acetylcholinesterase

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   43881   clinical trials with a EudraCT protocol, of which   7295   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    63 result(s) found for: Acetylcholinesterase. Displaying page 1 of 4.
    1  2  3  4  Next»
    EudraCT Number: 2004-002007-33 Sponsor Protocol Number: A2581078 Start Date*: 2004-11-25
    Sponsor Name:Pfizer Inc.
    Full Title: An 80-week, randomized, multi center, parallel group, double-blind study of the efficacy and safety of atorvastatin 80 mg plus an acetylcholinesterase inhibitor versus an acetylcholinesterase inhib...
    Medical condition: Alzheimer Disease
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed)
    Trial results: View results
    EudraCT Number: 2012-004765-40 Sponsor Protocol Number: 14863A Start Date*: 2014-03-31
    Sponsor Name:H. Lundbeck A/S
    Full Title: Randomised, double-blind, parallel-group, placebo-controlled study of Lu AE58054 in patients with mild-moderate Alzheimer’s disease treated with an acetylcholinesterase inhibitor; Study 3
    Medical condition: Alzheimer´s disease
    Disease: Version SOC Term Classification Code Term Level
    19.0 100000004852 10001896 Alzheimer's disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed) GB (Completed) DE (Completed) SK (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2018-000445-39 Sponsor Protocol Number: ACI-24-1801 Start Date*: 2018-06-19
    Sponsor Name:AC Immune SA
    Full Title: A Phase II Double-Blind, Randomized, Placebo-Controlled, Adaptive Design Study to Assess the Safety, Tolerability, Immunogenicity and Target Engagement of ACI-24 Formulations in Patients with Mild ...
    Medical condition: Alzheimer's Disease
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004852 10001896 Alzheimer's disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FI (Completed) SE (Completed) GB (GB - no longer in EU/EEA)
    Trial results: View results
    EudraCT Number: 2004-001174-25 Sponsor Protocol Number: NC501/SC01904 Start Date*: Information not available in EudraCT
    Sponsor Name:Neurocure Ltd
    Full Title: A DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO DETERMINE THE EFFICACY, SAFETY AND TOLERABILITY OF A COMBINATION OF GALANTAMINE (AN ACETYLCHOLINESTERASE INHIBITOR) PLUS TRIMIPRAMINE IN SMOKING CESSATION
    Medical condition: Healthy subjects who are smokers
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: IE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2019-001564-30 Sponsor Protocol Number: RA101495-02.301(RAISE) Start Date*: 2020-03-31
    Sponsor Name:Ra Pharmaceuticals, Inc.
    Full Title: A Phase 3, Multicenter, Randomized, Double Blind, Placebo-Controlled Study to Confirm the Safety, Tolerability, and Efficacy of Zilucoplan in Subjects with Generalized Myasthenia Gravis
    Medical condition: Generalized Myasthenia Gravis
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004859 10028415 Myasthenia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) NO (Completed) GB (GB - no longer in EU/EEA) ES (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2020-004848-29 Sponsor Protocol Number: NN6535-4730 Start Date*: 2021-04-29
    Sponsor Name:Novo Nordisk A/S
    Full Title: A randomised double-blind placebo-controlled clinical trial investigating the effect and safety of oral semaglutide in subjects with early Alzheimer´s disease (EVOKE)
    Medical condition: Mild cognitive impairment (MCI) or mild dementia, both of the Alzheimer’s type
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004852 10001896 Alzheimer's disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Trial now transitioned) CZ (Trial now transitioned) DE (Ongoing) FI (Trial now transitioned) IE (Trial now transitioned) SK (Trial now transitioned) NL (Trial now transitioned) AT (Trial now transitioned) BE (Trial now transitioned) SI (Ongoing) DK (Trial now transitioned) GR (Trial now transitioned) PL (Trial now transitioned) NO (Trial now transitioned) PT (Trial now transitioned) BG (Trial now transitioned) IT (Ongoing) FR (Ongoing) ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2014-001967-11 Sponsor Protocol Number: PBD01071 Start Date*: 2015-02-05
    Sponsor Name:Probiodrug AG
    Full Title: A Phase 2A Multicenter, Randomized, Double Blind, Placebo-Controlled, Parallel-Group Safety and Tolerability Trial of PQ912 in Subjects with early Alzheimer's Disease
    Medical condition: Early Stage Alzheimer's Disease
    Disease: Version SOC Term Classification Code Term Level
    19.0 10029205 - Nervous system disorders 10001896 Alzheimer's disease LLT
    19.0 10029205 - Nervous system disorders 10074616 Prodromal Alzheimer's disease PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed) FI (Completed) DE (Completed) SE (Completed) BE (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2006-001402-92 Sponsor Protocol Number: AVA102670 Start Date*: 2006-09-06
    Sponsor Name:GlaxoSmithKline R&D Limited
    Full Title: A 54-week, double-blind, randomized, placebo-controlled, parallel-group study to investigate the effects of rosiglitazone (extended release tablets) as adjunctive therapy to acetylcholinesterase in...
    Medical condition: Alzheimer's Disease
    Disease: Version SOC Term Classification Code Term Level
    8.1 10001896 Alzheimer's disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed) DE (Completed) GB (Completed) NL (Completed) FI (Completed) BE (Completed) CZ (Completed) SI (Completed) SK (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2020-004864-25 Sponsor Protocol Number: NN6535-4725 Start Date*: 2021-04-29
    Sponsor Name:Novo Nordisk A/S
    Full Title: A randomised double-blind placebo-controlled clinical trial investigating the effect and safety of oral semaglutide in subjects with early Alzheimer´s disease (EVOKE plus)
    Medical condition: Mild cognitive impairment (MCI) or mild dementia, both of the Alzheimer’s type
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004852 10001896 Alzheimer's disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Trial now transitioned) CZ (Trial now transitioned) DE (Ongoing) FI (Trial now transitioned) IE (Trial now transitioned) SK (Trial now transitioned) NL (Trial now transitioned) AT (Trial now transitioned) BE (Trial now transitioned) SI (Ongoing) DK (Ongoing) GR (Trial now transitioned) PL (Trial now transitioned) PT (Trial now transitioned) BG (Trial now transitioned) IT (Ongoing) ES (Ongoing) HR (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2006-004152-20 Sponsor Protocol Number: AVA 102675 Start Date*: 2007-11-16
    Sponsor Name:GlaxoSmithKline Research & Development
    Full Title: A 52-week open-label extension study of the long-term safety and efficacy of rosiglitazone extended-release (RSG XR) as adjunctive therapy to acetylcholinesterase inhibitors in subjects with mild-t...
    Medical condition: Mild-moderate Alzheimer disease
    Disease: Version SOC Term Classification Code Term Level
    6.1 10012271 PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Prematurely Ended) SE (Prematurely Ended) BE (Completed) ES (Completed) GR (Prematurely Ended) FR (Completed) CZ (Prematurely Ended) AT (Prematurely Ended) DE (Prematurely Ended) GB (Prematurely Ended) FI (Prematurely Ended) SI (Prematurely Ended) HU (Prematurely Ended) NL (Prematurely Ended) PT (Prematurely Ended) SK (Completed) BG (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2004-001336-22 Sponsor Protocol Number: AX-PC-201 Start Date*: 2004-11-03
    Sponsor Name:Axonyx Inc.
    Full Title: Effect of Phenserine Treatment on Amyloid in Brains of Patients with Mild Probable Alzheimer’s Disease as studied by Positron Emission Tomography (PET). A Randomised, three Months Double-Blind, Pla...
    Medical condition: Alzheimer’s Disease (AD) is the most common disease leading to dementia and it affects approximately 4 to 8% of the population aged above 65 years. The disease incidence is closely correlated with ...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2011-005292-17 Sponsor Protocol Number: TRx-237-008 Start Date*: 2012-10-02
    Sponsor Name:TauRx Therapeutics Ltd
    Full Title: A Double-Blind, Placebo-Controlled, Randomised, 4-Week Safety and Tolerability Study of LMTM in Subjects with Mild to Moderate Alzheimer’s Disease on Pre-Existing Stable Acetylcholinesterase Inhibi...
    Medical condition: Alzheimer’s Disease
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004852 10001896 Alzheimer's disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended) GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2010-020008-31 Sponsor Protocol Number: ACP-103-019 Start Date*: 2013-10-25
    Sponsor Name:ACADIA Pharmaceuticals Inc
    Full Title: A Single center, Double-Blind, Placebo-Controlled Study to Examine the Safety and Efficacy of Pimavanserin for the Treatment of Psychosis in Alzheimer’s Disease
    Medical condition: Psychosis associated with Alzheimer's disease
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2008-005260-14 Sponsor Protocol Number: ACI-91-0801 Start Date*: 2008-11-26
    Sponsor Name:AC Immune SA
    Full Title: A double-blind placebo-controlled study of the safety, tolerability and efficacy of 12 months’ treatment with ACI-91 in patients with mild to moderate Alzheimer’s Disease
    Medical condition: Mild to moderate Alzheimer’s Disease
    Disease: Version SOC Term Classification Code Term Level
    14.0 10029205 - Nervous system disorders 10001896 Alzheimer's disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) AT (Completed)
    Trial results: View results
    EudraCT Number: 2017-003586-94 Sponsor Protocol Number: DONEPEZIL001 Start Date*: 2018-01-08
    Sponsor Name:Fakultní nemocnice Hradec Králové
    Full Title: Monitoring of changes in donepezil concentrations, biomarkers of oxidative stress and activity of acetylchonesterase in the cerebrospinal fluid and plasma of patients with Alzheimer disease.
    Medical condition: Alzheimer's disease
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004852 10001897 Alzheimer's disease (incl subtypes) HLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed)
    Trial results: (No results available)
    EudraCT Number: 2009-014388-38 Sponsor Protocol Number: NEUAZ1 Start Date*: 2009-09-28
    Sponsor Name:Neurim Pharmaceuticals Ltd
    Full Title: A double-blind, parallel group, randomized, placebo controlled study of the efficacy of Circadin® 2mg in alleviating sleep disturbances in patients with mild to moderate Alzheimer Disease (AD) tre...
    Medical condition: Insomnia in patients with mild to moderate Alzheimers Disease.
    Disease: Version SOC Term Classification Code Term Level
    10. 10036701 Primary Insomnia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2008-005472-27 Sponsor Protocol Number: 70639 Start Date*: 2009-03-30
    Sponsor Name:Medizinische Universität Innsbruck
    Full Title: Die antidementive Therapie mit Acetylcholinesteraseinhibitoren: Untersuchung von Plasmakonzentrationen, Arzneimittelinteraktionen und Therapieeffekt in Abhängigkeit von genetischen Polymorphismen
    Medical condition: Anhand der vorliegenden Studie soll untersucht werden, ob genetische Polymorphismen im CYP2D6-, im MDR1- oder im ACHE Gen mit sub- bzw. supratherapeutischen Wirkstoffspiegeln im Plasma, mit relevan...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed)
    Trial results: View results
    EudraCT Number: 2004-004120-12 Sponsor Protocol Number: AAB-001-202 Start Date*: 2005-05-27
    Sponsor Name:Elan Pharma Ltd
    Full Title: A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Multiple Ascending Dose, Safety, Tolerability, and Amyloid-Imaging Positron Emission Tomography (PET) Trial of AAB-001 (ELN116727) in Pa...
    Medical condition: Alzheimer’s Disease
    Disease: Version SOC Term Classification Code Term Level
    5.1 10001897 HLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) FI (Completed)
    Trial results: (No results available)
    EudraCT Number: 2012-000537-39 Sponsor Protocol Number: M11-428 Start Date*: 2012-09-28
    Sponsor Name:AbbVie Deutschland GmbH & Co. KG
    Full Title: Long-Term Safety and Tolerability of ABT-126 in Subjects with Mild-to-Moderate Alzheimer's Disease on Stable Doses of Acetylcholinesterase Inhibitors: An Open-Label Extension Study for Subjects Com...
    Medical condition: Alzheimer's disease
    Disease: Version SOC Term Classification Code Term Level
    16.0 100000004852 10001896 Alzheimer's disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended) DE (Prematurely Ended) GR (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2020-003272-41 Sponsor Protocol Number: R3918-MG-2018 Start Date*: 2022-05-23
    Sponsor Name:Regeneron Pharmaceuticals, Inc.
    Full Title: Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy in Patients with Symptomatic Generalized Myasthenia Gravis
    Medical condition: Generalized Myasthenia Gravis
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029205 - Nervous system disorders 10028417 Myasthenia gravis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Ongoing) ES (Ongoing) IT (Ongoing) BE (Ongoing) PL (Ongoing) DK (Ongoing) DE (Ongoing)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sun May 19 19:11:22 CEST 2024 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA